Dr. Sigrun Hallmeyer, MD
Claim this profileAdvocate Lutheran General Hospital
Area of expertise
Breast Cancer
Sigrun Hallmeyer, MD has run 5 trials for Breast Cancer. Some of their research focus areas include:
Cancer
Sigrun Hallmeyer, MD has run 4 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
Advocate Lutheran General Hospital
Advocate Illinois Masonic Medical Center
Clinical Trials Sigrun Hallmeyer, MD is currently running
Surgical Excision Margins
for Melanoma
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.
Recruiting
1 award
N/A
9 criteria
Social and Genetic Factors
for Lymphoma Survivors
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.
Recruiting
1 award
N/A
10 criteria
More about Sigrun Hallmeyer, MD
Clinical Trial Related
2 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Sigrun Hallmeyer, MD has experience with
- Nivolumab
- Paclitaxel
- Pembrolizumab
- Relatlimab
- BMS-986016
- Trastuzumab
Breakdown of trials Sigrun Hallmeyer, MD has run
Breast Cancer
Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sigrun Hallmeyer, MD specialize in?
Sigrun Hallmeyer, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved Stage II patients, or patients who are HER2 positive.
Is Sigrun Hallmeyer, MD currently recruiting for clinical trials?
Yes, Sigrun Hallmeyer, MD is currently recruiting for 5 clinical trials in Park Ridge Illinois. If you're interested in participating, you should apply.
Are there any treatments that Sigrun Hallmeyer, MD has studied deeply?
Yes, Sigrun Hallmeyer, MD has studied treatments such as Nivolumab, Paclitaxel, Pembrolizumab.
What is the best way to schedule an appointment with Sigrun Hallmeyer, MD?
Apply for one of the trials that Sigrun Hallmeyer, MD is conducting.
What is the office address of Sigrun Hallmeyer, MD?
The office of Sigrun Hallmeyer, MD is located at: Advocate Lutheran General Hospital, Park Ridge, Illinois 60068 United States. This is the address for their practice at the Advocate Lutheran General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.